Insights Archive
Filter by:
October 2, 2023
New Drug Spotlight: Arexvy, Abrysvo, and Beyfortus
In 2023, the U.S. Food & Drug Administration (FDA) approved three new vaccines for the prevention of Respiratory Syncytial Virus (RSV). RSV is a highly contagious, common respiratory virus that typically causes mild cold-like symptoms. However, it can cause serious illness in older adults and infants.
September 29, 2023
Insulin Update
Amidst growing public and government attention on insulin affordability, what do plan sponsors need to know as they plan coverage strategies in 2024 and beyond?
May 30, 2023
Weight loss drugs and pharmacy benefit coverage
As more people are lured to these medications with hopes of an effective weight loss solution, many plan sponsors are growing concerned about their impact on plan spend.
May 30, 2023
New Drug Spotlight: Amjevita
The launch of Amjevita, the first FDA-approved biosimilar for Humira, is big news for pharmacy benefit plan sponsors.
May 30, 2023
First in a new class
An estimated 8 million adults in the U.S. have psoriasis. Last month, the FDA approved Sotyktu (deucravacitinib), the first in a new class of oral medication to treat plaque psoriasis. Will this new product be revolutionary or evolutionary when it comes to plaque psoriasis therapy?
May 30, 2023
Are you watching this?
Alzheimer’s drug pipeline news: Biogen Inc. in partnership with Eisai Co. has released encouraging data about their new anti-amyloid monoclonal antibody therapy (lecanemab) currently in clinical trials.
May 8, 2023
The most expensive medicine in the world
Remarkably, 94% of participants in the supporting study who received Hemgenix were able to discontinue use of intravenous FIX infusions. This is an important consideration since FIX infusion therapy can cost of approximately $500,000–$750,000 per year.
March 28, 2023
Understanding Specialty Pharmacy for Health Plan Success Webinar
Learn more about specialty pharmacy for health plan success! Fairview’s Tim Affeldt, Vice President of Specialty & Infusion, will present specialty pharmacy’s history, current state, and future challenges in a rapidly changing industry.
December 8, 2022
Treatments for Rare Diseases
Currently, a significant proportion of the pharmaceutical development pipeline is represented by drugs used to treat rare diseases and, increasingly, gene therapies. For example, 44 drugs in ClearScript’s Brand Pipeline Forecast are used to treat rare diseases and are up for approval in the upcoming six months.